Tafasitamab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AOTMIT (Poland), G-BA (Germany) and PBAC (Australia), among others, recommended or restricted tafasitamab, while CIPM (Spain), DMC (Denmark) and HAS (France), among others, did not recommend it.
Assessment has run over 5 years, from 30 Jul 2021 at AWMSG (Wales) to 29 Jul 2026 at AWMSG (Wales).
No assessment is on file from PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
Not every gap is a refusal: for tafasitamab, 1 submission was never made — an outcome set by the company rather than the assessor.
The file is active: 11 of 16 records date from 2023 or later.
Against its own class, tafasitamab is an outlier: 36% of its decisive outcomes were positive, where molecules sharing ATC class L01F average 73%.
6 distinct indication wordings are recorded for tafasitamab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
2 of these 16 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess tafasitamab, on 30 Jul 2021; G-BA (Germany) did not open a file until 2 Jul 2026 — a wide spread of 5 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 5 years in total.
4 of the 12 agencies here assessed tafasitamab more than once, AWMSG (Wales) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
tafasitamab has been through 12 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for tafasitamab reads 7 not recommended, 2 deferred to NICE, 2 restricted and 2 recommended, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| G-BA (Germany) | 2 Jul 2026 | Minjuvi — benefit assessment §35a | added benefit: non-quantifiable (hint) | source |
| PBAC (Australia) | 2026 | Relapsed and/or refractory follicular lymphoma (FL) | Recommended | source |
| DMC (Denmark) | 24 Jun 2026 | Tafasitamab i kombination med lenalidomid og rituximab til behandling af voksne patienter med recidiverende eller refrak… | Ikke anbefalet | source |
| SMC (Scotland) | 8 Jun 2026 | Tafasitamab is indicated in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) (Grade 1-… | not recommended | source |
| AOTMIT (Poland) | 25 Apr 2025 | programu lekowego B.12.FM. Leczenie chorych na chłoniaki B-komórkowe (ICD-10: C82, C83, C85) Prezes Agencji rekomenduje … | recommended | source |
11 further decisions for tafasitamab, across 10 agencies, are not shown here. They include the most recent record on file, 29 Jul 2026 from AWMSG (Wales); its outcome is in the subscriber dataset. They link to 10 further source documents.
Related molecules
- pembrolizumab — same ATC class L01F — Antineoplastics
- nivolumab — same ATC class L01F — Antineoplastics
- daratumumab — same ATC class L01F — Antineoplastics
- rituximab — same ATC class L01F — Antineoplastics
- bevacizumab — same ATC class L01F — Antineoplastics
- blinatumomab — same ATC class L01F — Antineoplastics
Coverage: 16 decisions for tafasitamab from 12 agencies, 2021 to 2026. Data to 7 Sep 2026. ATC class L01F — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.